Ποια είναι η τιμή για Walvax Biotechnology Co., Ltd. (300142)

Η τιμή για Walvax Biotechnology Co., Ltd. (300142) είναι $2.21

Ποια είναι η κεφαλαιοποίηση αγοράς για Walvax Biotechnology Co., Ltd. (300142)

Η κεφαλαιοποίηση αγοράς για Walvax Biotechnology Co., Ltd. (300142) είναι $3.54B

Walvax Biotechnology Co., Ltd. (300142) Τιμή και Κεφαλαιοποίηση Αγοράς

Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.

Η τιμή για 300142	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$3,181.21 $3.54B	NVDA	$5.088T	+143,755.93%
$2,894.36 $3.54B	AAPL	$4.629T	+130,784.35%
$2,574.54 $3.54B	GOOG	$4.118T	+116,322.12%
$2,305.13 $3.54B	MSFT	$3.687T	+104,139.30%
$1,750.49 $3.54B	AMZN	$2.800T	+79,058.03%

Η τιμή για 300142

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$3,181.21 $3.54B